 |
TSO3 registered on the new list established by the Autorité des marchés financiers as part of the SME Growth Stock PlanNovember 18, 2005Québec City, November 18, 2005 – TSO3 Inc. (“TSO3”) (TSX: TOS) announced today that it has obtained a decision from the Ministère du Revenu du Québec to the effect that the common shares of TSO3 are now registered on the list established by the Autorité des marchés financiers (AMF) and constitute eligible shares within the SME Growth Stock Plan, in compliance with the measures announced in the 2005-2006 Québec Budget, on April 21, 2005.As a result, common shares of TSO3 purchased on the secondary market to replace a qualifying share or security disposed of by an individual qualify as valid shares for a "coverage" operation in accordance with the SME Growth Stock Plan. “We are very happy to announce the eligibility of TSO3 common shares under the SME Growth Stock Plan. The aim of this exercise is not to proceed with a share issue in the short term. However, we are always looking for initiatives that can promote the trading of our stocks on the secondary markets,” explained Jocelyn Vézina, President and CEO of TSO3. For further information on the SME Growth Stock Plan, consult the Web site for the ministère du Revenu du Québec at www.revenu.gouv.qc.ca About TSO3 TSO3 Inc. is located in Québec City, Canada, and was founded in 1998. The Company’s mission is to develop and market innovate and comprehensive sterilization solutions. TSO3 has perfected an innovative sterilization process using ozone as the sterilizing agent. The first product based on this technological platform is the 125L Ozone Sterilizer, which is intended for hospital sterilization units. The 125L – named after its 125-litre/4.3-cubic-foot capacity – was designed to sterilize heat- and moisture-sensitive surgical and diagnostic devices which are expensive and in high demand from the surgical suite. The ozone sterilization process is a safe, efficacious, fast and cost-effective response to evolving sterilization needs. The 125L Ozone Sterilizer from TSO3 was cleared for commercialization by Health Canada and more recently by the U.S. Food and Drug Administration. TSO3 expects the first sales of this product in 2005. TSO3 currently has 53 employees, 16 of whom work in the sales and marketing team to support SKYTRON, the Company’s exclusive distributor for North America. With over 30 years experience servicing operating room and decontamination-sterilization departments throughout North America, SKYTRON provides 120 sales representatives, 100 service representatives and sales support facilities with manufacturing suppliers in the United States, Canada, Finland, Japan and the Netherlands to support the sales activities of TSO3. The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it. - 30 - Source: TSO3 Inc. Information: Caroline Côté Director, Corporate Communications and Investor Relations 418 651-0003, Extension 237 Email: ccote@tso3.com |
© 2005-2008 TSO3. All Rights Reserved.
